Skip to content

PSX Pharmaceuticals

ABOT Abbott Laboratories (Pakistan) Limited

Latest results: FY2025 · Dec 2025 Q2 FY2026 · Apr – Jun 2026

FY2025 revenue Rs 75.4 bn (+10.6%), profit Rs 8.0 bn (+52.2%). Dividend paid 2 years in a row.

Last close · 13 Nov 2026

Rs 1,000.00 ▲ 5.21 (+0.52%)

▼ 8.1% 1 year

15 Oct 22 Oct 28 Oct 3 Nov 11 Nov Jun Jul Aug Sep Oct Dec Feb May Jul Oct 2022 2023 2024 2025 2026
821.0052-week range1,274.00
Market cap
Rs 97.9 bn
P/E
11.4×
TTM to Jun 2026
Sector 12.6× · lower
P/B
3.05×
Quarter to Jun 2026
Sector 3.11×
Dividend yield
4.0%
FY2025
Payers 4.7% · lower
ROE
28.8%
FY2025
Sector 21.7% · higher
EPS
Rs 87.47
TTM to Jun 2026
Book value / share
Rs 327.85
Quarter to Jun 2026

Fundamentals

ABOT at a glance

Revenue · FY2025

Rs 75.4 bn

▲ 10.6% year on year

Profit attributable to shareholders · FY2025

Rs 8.0 bn

▲ 52.2% year on year

EPS – basic (Rs) · FY2025

Rs 81.37

▲ 52.2% year on year

Dividend per share (Rs) · FY2025

Rs 40.00

▲ 300.0% year on year

Net margin · FY2025

10.6%

+2.9 pts year on year

Debt to equity · FY2025

1.5%

+1.3 pts year on year

Price performance

ABOT returns

Close Rs 1,000.00
13 Nov 2026

Period Return Rs
MTD +3.5% −3.4 pts vs KSE +33.31
3M +8.2% +9.4 pts vs KSE +75.77
6M +13.6% +7.4 pts vs KSE +120.05
YTD −4.8% −7.0 pts vs KSE −50.14
1Y −8.1% −18.9 pts vs KSE −88.51
Long term
3Y +143.8% +34.6% a year −70.8 pts vs KSE +589.88
5Y +33.4% +5.9% a year −255.5 pts vs KSE +250.07

Price return from the last close before each period; the fiscal year ends 31 December, so year to date is also fiscal year to date. Dividends are not included.

Abbott Laboratories (Pakistan) Limited in brief

Abbott Laboratories (Pakistan) Limited (ABOT) reported revenue of Rs 75.4 bn for FY2025 (Jan – Dec 2025), up 10.6% from FY2024.

Profit attributable to shareholders was Rs 8.0 bn (EPS Rs 81.37), up 52.2%, a net margin of 10.6%.

It declared a dividend of Rs 40.00 per share for FY2025.

The balance sheet showed net cash of Rs 12.8 bn.

Return on equity was 28.8%.

Over the last five years revenue grew at a compound 16.4% a year.

At Rs 1,000.00 (close on 13 Nov 2026) the shares trade at 11.4× earnings (TTM to Jun 2026) and 3.05× book value, with a dividend yield of 4.0%.

Scorecard vs Pharmaceuticals

14 companies
Growth
Below average
15.2%
Profitability
Average
10.6%
Financial health
Strong
1.5%
Valuation
Above average
11.4×
Dividends
Above average
4.0%

Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.

Corporate

ABOT announcements & payouts

All ABOT announcements →
27 Oct 2026 · 15:19
Result · Nine months to 30 Sep 2026
Profit after tax
Rs 6,684.2 mn
EPS
Rs 68.28 +24.6%
EPS a year earlier
Rs 54.81
28 Aug 2026 · 16:29
Result · Half year to 30 Jun 2026
Profit after tax
Rs 4,140.2 mn
EPS
Rs 42.29 +16.9%
EPS a year earlier
Rs 36.19
28 Apr 2026 · 11:42
Result · First quarter to 31 Mar 2026
Profit after tax
Rs 1,940.3 mn
EPS
Rs 19.82 +21.3%
EPS a year earlier
Rs 16.34
16 Mar 2026 · 14:30
Result · Full year to 31 Dec 2025 Cash 400% · Rs 40.00 · Final AGM 30 Apr
Profit after tax
Rs 7,966.5 mn
EPS
Rs 81.37 +52.2%
EPS a year earlier
Rs 53.46

Book closure 23 Apr – 30 Apr 2026 · Buy by Mon 20 Apr (est.) for the payout

Financial highlights

ABOT financial results

ABOT annual financial highlights (Rs bn)
Rs bn FY2025 Jan – Dec 2025 FY2024 Jan – Dec 2024 FY2023 Jan – Dec 2023 FY2022 Jan – Dec 2022 FY2021 Jan – Dec 2021 FY2020 Jan – Dec 2020 FY2019 Jan – Dec 2019 FY2018 Jan – Dec 2018 FY2017 Jan – Dec 2017 FY2016 Jan – Dec 2016
Revenue 75.4 68.2 55.5 49.3 42.6 35.3 30.2 29.7 26.1 23.4
Gross profit 26.8 20.0 11.8 14.5 16.1 12.2 8.5 9.8 10.1 9.4
Operating profit 13.2 8.9 3.2 6.1 7.8 6.1 2.5 4.4 5.5 5.2
Profit after tax 8.0 5.2 0.3 3.0 6.0 4.5 1.3 2.7 4.2 4.0
Profit attributable to shareholders 8.0 5.2 0.3 3.0 6.0 4.5 1.3 2.7 4.2 4.0
EPS – basic (Rs) Rs 81.37 53.46 2.67 30.69 60.95 46.33 13.28 27.52 42.95 41.08
Dividend per share (Rs) Rs 40.00 10.00 0.00 15.00 40.00 40.00 7.50 20.00 40.00 40.00
Total assets 46.8 37.7 36.7 33.9 28.6 24.9 20.8 20.3 19.2 17.6
Total equity 31.6 23.7 18.2 17.1 17.4 15.6 13.4 13.2 14.4 14.6
Total debt 0.5 0.1 0.2 0.2 0.2 0.8 0.4 0.2 0.0 —
Net cash from operating activities 11.2 5.1 0.7 4.7 8.4 8.5 0.1 3.3 6.1 3.5
Capital expenditure (3.3) (3.0) (3.1) (3.6) (2.1) (1.4) (1.9) (2.3) (1.6) (1.0)
Free cash flow (operating cash flow − capex) 7.9 2.1 (2.4) 1.1 6.3 7.1 (1.8) 1.0 4.5 2.5
ABOT quarterly financial highlights (Rs bn)
Rs bn TTM to Jun 2026 Q2 FY2026 Apr – Jun 2026 Q1 FY2026 Jan – Mar 2026 Q4 FY2025 Oct – Dec 2025 Q3 FY2025 Jul – Sep 2025 Q2 FY2025 Apr – Jun 2025 Q1 FY2025 Jan – Mar 2025 Q4 FY2024 Oct – Dec 2024 Q3 FY2024 Jul – Sep 2024
Revenue 77.0 20.3 17.7 19.2 19.8 19.1 17.3 18.6 17.4
Gross profit 28.3 7.8 6.7 7.1 6.7 6.8 5.8 5.6 5.8
Operating profit 13.8 3.7 3.1 3.9 3.1 3.3 2.6 3.1 2.9
Profit after tax 8.6 2.2 1.9 2.6 1.8 1.9 1.6 1.3 1.8
Profit attributable to shareholders 8.6 2.2 1.9 2.6 1.8 1.9 1.6 1.3 1.8
EPS – basic (Rs) Rs 87.47 22.47 19.82 26.56 18.62 19.85 16.34 13.12 18.48
Dividend per share (Rs) Rs 40.00 0.00 0.00 40.00 0.00 0.00 0.00 10.00 0.00
Total assets 48.8 48.8 50.2 46.8 44.5 42.2 39.3 37.7 37.3
Total equity 32.1 32.1 33.7 31.6 28.4 26.4 24.4 23.7 22.4
Total debt 0.4 0.4 0.5 0.5 0.4 0.5 0.1 0.1 0.1
Net cash from operating activities 9.1 1.5 (0.4) 5.8 2.2 2.3 0.9 3.3 1.2
Capital expenditure (2.8) (0.6) (0.5) (1.4) (0.3) (0.9) (0.6) (1.1) (0.9)
Free cash flow (operating cash flow − capex) 6.2 0.8 (0.9) 4.4 1.9 1.4 0.3 2.2 0.3

Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 26 Oct 2026.

ABOT charts

Revenue and profit Revenue Profit attributable
Revenue and profit Rs 75 bn Revenue FY16: Rs 23.4 bn Profit attributable FY16: Rs 4.0 bn FY16 Revenue FY17: Rs 26.1 bn Profit attributable FY17: Rs 4.2 bn FY17 Revenue FY18: Rs 29.7 bn Profit attributable FY18: Rs 2.7 bn FY18 Revenue FY19: Rs 30.2 bn Profit attributable FY19: Rs 1.3 bn FY19 Revenue FY20: Rs 35.3 bn Profit attributable FY20: Rs 4.5 bn FY20 Revenue FY21: Rs 42.6 bn Profit attributable FY21: Rs 6.0 bn FY21 Revenue FY22: Rs 49.3 bn Profit attributable FY22: Rs 3.0 bn FY22 Revenue FY23: Rs 55.5 bn Profit attributable FY23: Rs 261.8 mn FY23 Revenue FY24: Rs 68.2 bn Profit attributable FY24: Rs 5.2 bn FY24 Revenue FY25: Rs 75.4 bn Profit attributable FY25: Rs 8.0 bn FY25
Margins Gross margin Operating margin Net margin
Margins 43% 22% 0% Gross margin FY16: 40.1% Gross margin FY17: 38.7% Gross margin FY18: 33.0% Gross margin FY19: 28.3% Gross margin FY20: 34.6% Gross margin FY21: 37.8% Gross margin FY22: 29.5% Gross margin FY23: 21.3% Gross margin FY24: 29.3% Gross margin FY25: 35.5% Operating margin FY16: 22.3% Operating margin FY17: 21.2% Operating margin FY18: 14.7% Operating margin FY19: 8.4% Operating margin FY20: 17.2% Operating margin FY21: 18.3% Operating margin FY22: 12.4% Operating margin FY23: 5.8% Operating margin FY24: 13.0% Operating margin FY25: 17.5% Net margin FY16: 17.2% Net margin FY17: 16.1% Net margin FY18: 9.1% Net margin FY19: 4.3% Net margin FY20: 12.9% Net margin FY21: 14.0% Net margin FY22: 6.1% Net margin FY23: 0.5% Net margin FY24: 7.7% Net margin FY25: 10.6% FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25
Cash flow Operating cash flow Capex Free cash flow
Cash flow Rs 11 bn -Rs 4 bn Operating cash flow FY16: Rs 3.5 bn Capex FY16: -Rs 986.8 mn Free cash flow FY16: Rs 2.5 bn FY16 Operating cash flow FY17: Rs 6.1 bn Capex FY17: -Rs 1.6 bn Free cash flow FY17: Rs 4.5 bn FY17 Operating cash flow FY18: Rs 3.3 bn Capex FY18: -Rs 2.3 bn Free cash flow FY18: Rs 966.8 mn FY18 Operating cash flow FY19: Rs 101.9 mn Capex FY19: -Rs 1.9 bn Free cash flow FY19: -Rs 1.8 bn FY19 Operating cash flow FY20: Rs 8.5 bn Capex FY20: -Rs 1.4 bn Free cash flow FY20: Rs 7.1 bn FY20 Operating cash flow FY21: Rs 8.4 bn Capex FY21: -Rs 2.1 bn Free cash flow FY21: Rs 6.3 bn FY21 Operating cash flow FY22: Rs 4.7 bn Capex FY22: -Rs 3.6 bn Free cash flow FY22: Rs 1.1 bn FY22 Operating cash flow FY23: Rs 673.3 mn Capex FY23: -Rs 3.1 bn Free cash flow FY23: -Rs 2.4 bn FY23 Operating cash flow FY24: Rs 5.1 bn Capex FY24: -Rs 3.0 bn Free cash flow FY24: Rs 2.1 bn FY24 Operating cash flow FY25: Rs 11.2 bn Capex FY25: -Rs 3.3 bn Free cash flow FY25: Rs 7.9 bn FY25

Valuation

ABOT valuation at today's price

Price to earnings (P/E)
11.4×
EPS Rs 87.47 (TTM to Jun 2026)
Price to book (P/B)
3.05×
Book value Rs 327.85 (Quarter to Jun 2026)
Dividend yield
4.0%
DPS Rs 40.00 (FY2025)
Earnings yield
8.7%
EPS ÷ price

At the closing price of Rs 1,000.00 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.

Sector peers

ABOT vs Pharmaceuticals companies

Largest companies in the sector at today's prices
Company Market cap P/E P/B Yield ROE 3-yr growth
ABOT Rs 97.9 bn 11.4× 3.05× 4.0% 28.8% 15.2%
GLAXO Rs 107.1 bn 10.3× 3.11× 5.1% 32.4% 16.3%
HALEON Rs 81.6 bn 12.4× 5.02× 4.3% 47.6% 16.2%
HINOON Rs 50.8 bn 12.8× 3.95× 5.2% 32.3% 20.5%
AGP Rs 43.8 bn 11.7× 2.92× 5.1% 25.9% 26.0%
HPL Rs 38.5 bn 10.3× 4.50× 6.0% 38.6% 18.6%
FEROZ Rs 15.8 bn 16.1× 1.19× 1.5% 7.6% 27.9%
CPHL Rs 14.5 bn 18.3× 1.34× 0.0% 7.3% 4.3%
MACTER Rs 12.0 bn 17.7× 2.87× 0.0% 17.4% 20.7%

All Pharmaceuticals companies, medians and leaders →

Rankings

Where ABOT ranks on PSX

Compare

Compare ABOT with

Analyses & signals 0

Win rate — · 0 closed signals · average return —

No analyses published for ABOT yet.

ABOT: frequently asked questions

What is ABOT's EPS?

Abbott Laboratories (Pakistan) Limited reported basic earnings per share of Rs 81.37 for FY2025 (Jan – Dec 2025). Over the trailing twelve months (TTM to Jun 2026) EPS was Rs 87.47.

What is ABOT's P/E ratio?

At the closing price of Rs 1,000.00 on 13 Nov 2026, ABOT trades at a P/E of 11.4× based on EPS of Rs 87.47 (TTM to Jun 2026).

Does ABOT pay dividends?

Yes. Abbott Laboratories (Pakistan) Limited declared a dividend of Rs 40.00 per share for FY2025. It has paid a dividend in each of the last 2 years. At Rs 1,000.00 that is a dividend yield of 4.0%.

What was ABOT's revenue and profit in FY2025?

Abbott Laboratories (Pakistan) Limited reported revenue of Rs 75.4 bn and profit attributable to shareholders of Rs 8.0 bn for FY2025 (Jan – Dec 2025).

What is ABOT's book value per share?

Abbott Laboratories (Pakistan) Limited's book value per share was Rs 323.04 at the end of FY2025. The shares trade at 3.05× book value.

How has ABOT's share price performed?

ABOT's share price is down 4.8% year to date (KSE-100: +2.2%), down 8.1% over one year (KSE-100: +10.7%) and up 33.4% over five years (KSE-100: +288.8%), as of 13 Nov 2026. These are price returns; dividends are not included.

Information only, not investment advice.